Korea Hypertension Fact Sheet 2023: analysis of nationwide population-based data with a particular focus on hypertension in special populations
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
The Korea Hypertension Fact Sheet 2023, presented by the Korean Society of Hypertension, offers an overview of the prevalence and management of hypertension, along with recent trends.Data for the Fact Sheet were derived from the Korea National Health and Nutrition Examination Survey spanning 1998 to 2021, and the National Health Insurance Big Data from 2002 to 2021.As of 2021, hypertension affected 28.0% of Korean adults aged 20 and older, totaling approximately 12.3 million individuals, with 5.3 million (43.5%) aged 65 or older. Among those with hypertension, awareness stood at 74.1%, treatment rates at 70.3%, and control rates at 56.0%. Over the years, the number of hypertension diagnoses increased from 3.0 million in 2002 to 11.1 million in 2021. During the same period, the utilization of antihypertensive medications rose from 2.5 million to 10.5 million, with treatment adherence also improving from 0.6 million to 7.8 million individuals. In 2021, the predominant antihypertensive drug class was angiotensin receptor blockers (75.1%), followed by calcium channel blockers (61.7%), diuretics (23.4%), and beta blockers (15.3%). Notably, 60.2% of all antihypertensive prescriptions involved combination therapy with at least two classes of antihypertensive medication. There was a positive trend towards stricter blood pressure control targets (systolic/diastolic blood pressure < 130/80 mmHg) among elderly hypertensive patients, as well as those with diabetes, obesity, and high-risk hypertension. However, this trend declined in individuals aged 80 years or older and those with chronic kidney disease in recent years.In Korea, hypertension management is making strides, yet the total number of hypertensive individuals is rising. Effectively addressing the growing population of elderly hypertensive patients and the persistently low treatment rates among younger individuals with hypertension is a critical challenge. Additionally, developing more efficient and customized policies for blood pressure control and cardiovascular disease prevention is imperative.
Abstract
Background The Korea Hypertension Fact Sheet 2023, presented by the Korean Society of Hypertension, ofers an overview of the prevalence and management of hypertension, along with recent trends. Methods Data for the Fact Sheet were derived from the Korea National Health and Nutrition Examination Survey spanning 1998 to 2021, and the National Health Insurance Big Data from 2002 to 2021. Results As of 2021, hypertension afected 28.0% of Korean adults aged 20 and older, totaling approximately 12.3 mil‑ lion individuals, with 5.3 million (43.5%) aged 65 or older. Among those with hypertension, awareness stood at 74.1%, treatment rates at 70.3%, and control rates at 56.0%. Over the years, the number of hypertension diagnoses increased from 3.0 million in 2002 to 11.1 million in 2021. During the same period, the utilization of antihypertensive medica‑ tions rose from 2.5 million to 10.5 million, with treatment adherence also improving from 0.6 million to 7.8 million individuals. In 2021, the predominant antihypertensive drug class was angiotensin receptor blockers (75.1%), followed by calcium channel blockers (61.7%), diuretics (23.4%), and beta blockers (15.3%). Notably, 60.2% of all antihyper‑ tensive prescriptions involved combination therapy with at least two classes of antihypertensive medication. There was a positive trend towards stricter blood pressure control targets (systolic/diastolic blood pressure<130/80 mmHg) among elderly hypertensive patients, as well as those with diabetes, obesity, and high-risk hypertension. However, this trend declined in individuals aged 80 years or older and those with chronic kidney disease in recent years. Conclusion In Korea, hypertension management is making strides, yet the total number of hypertensive individu‑ als is rising. Efectively addressing the growing population of elderly hypertensive patients and the persistently low treatment rates among younger individuals with hypertension is a critical challenge. Additionally, developing more efcient and customized policies for blood pressure control and cardiovascular disease prevention is imperative.
참고문헌 (23)
- Lopez AD, "Global and regional burden of disease and risk factors, 2001 : systematic analysis of population health data", Lancet, 367(9524), pp.1747~1757 (2006)
- Feigin VL, "Global burden of stroke and risk factors in 188 countries, during 1990–2013 : a systematic analysis for the global burden of disease study 2013", Lancet Neurol, 15(9), pp.913~924 (2016)
- Zhou B, "Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 : a pooled analysis of 1201population-representative studies with 104 million participants", Lancet, 398(10304), pp.957~980 (2021)
- Baek J, "Thirty-six year trends in mortality from diseases of circulatory system in Korea", Korean Circulation J, 51(4), pp.320~332 (2021)
- Lee HH, "Korea Heart disease fact sheet 2020 : analysis of nationwide data", Korean Circulation J, 51(6), pp.495~503 (2021)
- Korean Society H, "Korea hypertension fact sheet 2018", Clin Hypertens, 24, pp.13~ (2018)
- Kim HC, "Korea hypertension fact sheet 2020 : analysis of nationwide population-based data", Clin Hypertens, 27(1), pp.8~ (2021)
- Kim HC, "Korea hypertension fact sheet 2021 : analysis of nationwide population-based data with special focus on hypertension in women", Clin Hypertens, 28(1), pp.1~5 (2022)
- Kim HC, "Korea hypertension fact sheet 2022 : analysis of nationwide population-based data with a special focus on hypertension in the elderly", Clin Hypertens, 29(1), pp.22~ (2023)
- Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
- Unger T, "2020 international society of hypertension global hypertension practice guidelines", Hypertension, 75(6), pp.1334~1357 (2020)
- Mancia G, "2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension(ISH)and the European Renal Association(ERA)", J Hypertens (2023)
- Kim HL, "The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension", Clin Hypertens, 29(1), pp.11~ (2023)
- Oh K, "Korea National health and nutrition examination survey, 20th anniversary : accomplishments and future directions", Epidemiol Health, 43, pp.e2021025~ (2021)
- Lee GB, "Obesity, hypertension, diabetes mellitus, and hypercholesterolemia in Korean adults before and during the COVID-19 pandemic : a special report of the 2020 Korea National Health and Nutrition Examination Survey", Epidemiol Health, 44, pp.1~2 (2022)
- Seong SC, "Data resource profile : the national health information database of the national health insurance service in South Korea", Int J Epidemiol, 46(3), pp.799~800 (2017)
- Soares AA, "Glomerular filtration rate measurement and prediction equations", Clin Chem Lab Med, 47(9), pp.1023~1032 (2009)
- O’Rourke K, "Cardiovascular disease worldwide, 1990-2013", JAMA, 314(18), pp.1905~ (2015)
- Kim KI, "2018 Korean society of hypertension guidelines for the management of hypertension : part III-hypertension in special situations", Clin Hypertens, 25, pp.19~ (2019)
- Choi JH, "2023 clinical practice guidelines for diabetes mellitus of the Korean diabetes association", Diabetes Metab J, 47(5), pp.575~594 (2023)
- Kidney Disease : Improving Global Outcomes Blood Pressure Work G, "KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease", Kidney Int, 99(3S), pp.S1~S87 (2021)
- Lee HH, "Cardiovascular implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease", J Am Coll Cardiol, 79(17), pp.1675~1686 (2022)
- Foti KE, "Potential implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease in the United States", Kidney Int, 99(3), pp.686~695 (2021)